But Bresch's testimony, and the EpiPen pricing scandal in general, shouldn't be viewed as just another CEO put on the hot seat to explain her company's questionable (to put it mildly) behavior.

When Mylan CEO Heather Bresch testifies before the House committee on Wednesday, she will defend the company's actions and try to justify what surely seem like outrageous, unsubstantiated price hikes to the average consumer.

Today, EpiPens, which cost Mylan around $30 to produce, go for over $600 before coupons or rebates. The fat payoffs rolled in during a period when the list prices for EpiPens soared, increasing over 500% in about a decade. Top executives at Mylan, the pharmaceutical company that owns EpiPen, reportedly reaped in nearly $300 million in compensation from 2011 to 2015. The meeting follows weeks of reports about outrageous price increases for the life-saving medication, an auto-injection system that provides a dose of epinephrine to ward off anaphylactic shock that can occur during an allergic reaction. On Wednesday afternoon, the House Committee on Oversight and Government Reform is hosting a hearing on EpiPen price increases.

Epic pen price